Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
October 24, 2024 07:30 ET
|
Soligenix, Inc.
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Nufactor® Receives URAC’s Full Certification as a Rare Disease Pharmacy Center of Excellence
September 17, 2024 13:34 ET
|
FFF Enterprises.com
TEMECULA, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nufactor, Inc., a specialty infusion company and subsidiary of FFF Enterprises, Inc., is delighted to announce that it has received full...
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
August 07, 2024 19:30 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a...
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
August 01, 2024 09:00 ET
|
PRISM Mediawire
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
Avance Clinical Announces Senior Appointment to North American Operations
July 31, 2024 02:45 ET
|
Avance Clinical
ADELAIDE, Australia and WAKE FOREST, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, an award-winning, mid-sized full-service global Contract Research Organization (CRO) for biotech...
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
July 15, 2024 10:16 ET
|
PRISM MarketView
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
Jura Health Welcomed by Colorado Medicaid as an Approved Provider for Testing for Suspected Rare Diseases
June 20, 2024 11:55 ET
|
Innosphere Ventures
Denver, Colorado, June 20, 2024 (GLOBE NEWSWIRE) -- Jura Health, an Innosphere Ventures client company, committed to health equity for rare disease patients and their families, is pleased to...
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
June 05, 2024 08:00 ET
|
PRISM MarketView
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
TrialWire Patient Recruitment Platform that Reboots Stalled Clinical Trials announced as Multi-Award Finalist in the 2024 Citeline Awards
May 12, 2024 16:29 ET
|
TrialWire
The TrialWire™ Rapid Patient Recruitment Platform, the only pay-per-enrolled fixed-fee solution powered by AI and algorithms, has been select for 3 awards
Using AI to Improve Diagnosis of Rare Genetic Disorders
April 25, 2024 09:19 ET
|
Baylor Genetics
Diagnosing rare Mendelian disorders is a labor-intensive task, even for experienced geneticists. Investigators at Baylor College of Medicine are trying to